42.1 F
Washington D.C.
Sunday, January 29, 2023

Ebola ‘No Longer Incurable’ as Drug Combo Tried in DRC Outbreak

A new study in the BMJ has identified two new drugs, mAb114 and REGN-EB3, that can dramatically cut mortality from Ebola, and both are being immediately offered to all patients in an effort to control the Democratic Republic of Congo’s (DRC) worst ever outbreak.

The trial initially compared four potential treatments proposed by four different companies: ZMapp, remdesivir, mAb114, and REGN-EB3, and preliminary data convinced the trial’s monitoring board to stop the study and randomise all remaining patients to either mAb114 or REGN-EB3.

Data from the first 499 patients showed that REGN-EB3 had met early stopping criteria, and mAb114 was ‘not far behind’. Among all patients who took the drugs, those treated with REGN-EB3 had a mortality rate of 29%, while those who got mAb-114 had a mortality rate of 34%.

Read more at PharmaTimes

Homeland Security Todayhttp://www.hstoday.us
The Government Technology & Services Coalition's Homeland Security Today (HSToday) is the premier news and information resource for the homeland security community, dedicated to elevating the discussions and insights that can support a safe and secure nation. A non-profit magazine and media platform, HSToday provides readers with the whole story, placing facts and comments in context to inform debate and drive realistic solutions to some of the nation’s most vexing security challenges.

Related Articles

- Advertisement -

Latest Articles